The global Epstein - Barr virus diagnosis and treatment market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period (2023-2030). Epstein - Barr virus (EBV) is a type of the herpes virus, also known as human herpesvirus . It is a highly common human virus that spreads through body fluids, primarily saliva. Moreover, it can also spread through blood transfusions, and organ transplantations among other causes. This infection is generally contracted during childhood. Growing incidence of Epstein-Barr virus infection is anticipated to drive the market demand. According to an article published in Frontiers in Oncology, Epstein-Barr virus is highly prevalent and it affects more than 90.0% individuals globally. Moreover, EBV sero prevalence increased with age and hence, a surge in the geriatric population is likely to fuel the market growth.
Browse the full report description of “Epstein - Barr Virus Diagnosis And Treatment Market Size, Share & Trends Analysis Report by Treatment (lab based test and POC test), by Diagnosis (antiviral drugs (Acyclovir, Ganciclovir, Desciclovir), and Other Drugs (Anti-inflammatory, Antipyretic and other)), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/epstein-barr-virus-diagnosis-and-treatment-market
The increasing patient demand for individualized care, personalized pharmaceuticals are further propelling the market growth globally. In December 2022, the European Commission (EC) has granted the first approval of an allogeneic T-cell immunotherapy globally, a marketing authorization for Ebvallo (tabelecleucel) for patients over two years of old with relapsed or refractory Epstein Barr virus positive post transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. As the first allogeneic, or donor-derived, T-cell immunotherapy to receive approval from any regulatory agency in the world. The approval follows the Committee for Medicinal Products for Human Use (CHMP)’s positive opinion given in October 2022 and is applicable to all 27 European Union Member States plus Iceland, Norway, and Liechtenstein. The CHMP positive opinion is based on results from the pivotal Phase III ALLELE study, which showed Ebvallo demonstrated a favorable risk-benefit profile.
Further, in August 2023, Manulife announced that its Personalized Medicine program (known industry-wide as pharmacogenomics) will now be available for Extended Health Care members with certain qualifying conditions at no additional cost. This simple, one-time genetic test, done via a saliva sample that takes less than a minute, helps predict how effective certain medications may be depending on an individual's genetic makeup. Based on the results, health care practitioners can then tailor treatment plans that are personalized and precise, reducing side effects and increasing the odds of successful patient outcomes. Such developments are contributing to the market growth.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By diagnosis
o By Treatment
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes, Advenchen Laboratories LLC, Arno Therapeutics Inc, bluebird bio Inc, Cell Medica Ltd, Epiphany Biosciences Inc, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Epstein - Barr virus diagnosis and TreatmentMarket Report Segment
By diagnosis
By treatment
Global Epstein - Barr virus diagnosis and Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/epstein-barr-virus-diagnosis-and-treatment-market